JP2024522304A - Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体 - Google Patents

Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体 Download PDF

Info

Publication number
JP2024522304A
JP2024522304A JP2024518956A JP2024518956A JP2024522304A JP 2024522304 A JP2024522304 A JP 2024522304A JP 2024518956 A JP2024518956 A JP 2024518956A JP 2024518956 A JP2024518956 A JP 2024518956A JP 2024522304 A JP2024522304 A JP 2024522304A
Authority
JP
Japan
Prior art keywords
cancer
compound
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522304A5 (https=
JPWO2022256680A5 (https=
Inventor
ギラッド、オーレン
ヴァッカ、ジョセフ
Original Assignee
アプレラ セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプレラ セラピューティクス、インク． filed Critical アプレラ セラピューティクス、インク．
Publication of JP2024522304A publication Critical patent/JP2024522304A/ja
Publication of JP2024522304A5 publication Critical patent/JP2024522304A5/ja
Publication of JPWO2022256680A5 publication Critical patent/JPWO2022256680A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024518956A 2021-06-04 2022-06-03 Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体 Pending JP2024522304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2024522304A true JP2024522304A (ja) 2024-06-13
JP2024522304A5 JP2024522304A5 (https=) 2025-06-10
JPWO2022256680A5 JPWO2022256680A5 (https=) 2025-06-10

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518956A Pending JP2024522304A (ja) 2021-06-04 2022-06-03 Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体

Country Status (10)

Country Link
US (1) US20240254123A1 (https=)
EP (1) EP4347592A1 (https=)
JP (1) JP2024522304A (https=)
KR (1) KR20240044409A (https=)
CN (1) CN117794932A (https=)
AU (2) AU2022287033B2 (https=)
CA (1) CA3225152A1 (https=)
IL (1) IL309037A (https=)
MX (1) MX2023014466A (https=)
WO (1) WO2022256680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126128A1 (ja) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. ジヒドロピラゾロピリミジノン誘導体
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
JP2016516763A (ja) * 2013-04-11 2016-06-09 アルマック・ディスカバリー・リミテッドＡｌｍａｃ Ｄｉｓｃｏｖｅｒｙ Ｌｉｍｉｔｅｄ ２−アミノピリド［４，３−Ｄ］ピリミジン−５−オン誘導体及びＷｅｅ−１阻害薬としてのそれらの使用
WO2018011570A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyridopyrimidinone compounds
WO2019138227A1 (en) * 2018-01-10 2019-07-18 Almac Discovery Limited Pharmaceutical compounds
JP2020529993A (ja) * 2017-08-01 2020-10-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー １，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン類似体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126128A1 (ja) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. ジヒドロピラゾロピリミジノン誘導体
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
JP2016516763A (ja) * 2013-04-11 2016-06-09 アルマック・ディスカバリー・リミテッドＡｌｍａｃ Ｄｉｓｃｏｖｅｒｙ Ｌｉｍｉｔｅｄ ２−アミノピリド［４，３−Ｄ］ピリミジン−５−オン誘導体及びＷｅｅ−１阻害薬としてのそれらの使用
WO2018011570A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyridopyrimidinone compounds
JP2020529993A (ja) * 2017-08-01 2020-10-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー １，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン類似体
WO2019138227A1 (en) * 2018-01-10 2019-07-18 Almac Discovery Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
KR20240044409A (ko) 2024-04-04
AU2022287033A1 (en) 2024-01-18
AU2022287033B2 (en) 2025-04-17
CN117794932A (zh) 2024-03-29
WO2022256680A1 (en) 2022-12-08
US20240254123A1 (en) 2024-08-01
IL309037A (en) 2024-02-01
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
AU2021286264B2 (en) Use of inhibitors of Bruton's tyrosine kinase (Btk)
JP2024522304A (ja) Ｗｅｅ１キナーゼ阻害剤として有用なピリドピリミジン誘導体
US20240316004A1 (en) Methods of treating mutant lymphomas
CA3154024C (en) Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US11084829B2 (en) Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
CA3080971A1 (en) Modulators of the integrated stress pathway
CA3081750A1 (en) Anticancer agents
US20190142834A1 (en) Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
RS62496B1 (sr) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu
HK40107981A (zh) 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
AU2015275321A1 (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224